Special Feature "Medical DX
Digital and Data Pioneering the Frontiers of DX in Japanese Medicine
Medical DX" is the key to delivering optimal, high-quality medical care in Japan, where the population is declining and aging. From interviews with former Digital Agency experts, to the JPMA task force's promotion of data consolidation, to the latest trends in AI drug discovery, this issue introduces "co-creation" efforts that transcend industry boundaries.
From JPMA
Interview with Mae Mori, Executive Vice President: Creating Value Together - Truly Patient-Centered Medicine through Co-creation
Former Executive Director Mori, who retired in September of this year, will talk about the philosophy of "Co-creation" that goes beyond the conventional "Patient Centricity" and how it has been put into practice in JPMA. He will talk about the improvement of information access and the "Co-creation Meeting" to revitalize the organization, as well as how to pass it on to the next generation.
My Committee
vol.4 Environmental Issue Committee
The pharmaceutical industry accounts for about 90% of GHG emissions, and the industry is working to decarbonize its Scope 3 (the entire supply chain). Following the adoption of a model project by the Ministry of the Environment, we will introduce the activities of the Environmental Issue Committee, which is working on "co-creation" to establish guidelines for industry-wide Scope 3 calculation and primary data generation.
The Pharmaceutical Industry from a Factual Perspective
Survey on EBP-derived drugs in the U.S.
The success factors of EBPs in the U.S., which are increasing their presence as drug discovery modalities diversify, will be examined in depth from the four facts of "funding strategy," "diverse human resources," "collaborative structure," and "business orientation," and specific suggestions for revitalizing the drug discovery ecosystem in Japan will be explored.
Topics
Introducing various topics within the association
We will present the latest developments, including students' perception of the JPMA's Vision for 2035 as a "challenging industry," the JPMA's first "Co-creation Meeting" to realize the Vision, and the release of the TPP, a common language for drug research and development that encourages collaboration among academia.
Please click here to send us your comments on the renewed Newsletter. ／Readers' Questionnaire